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Summary
Background Medication nonadherence is known to limit the effectiveness of avail-
able therapies; however, little is known specifically about medication adherence
in people with psoriasis. Medicines self-management can feel onerous to those
with dermatological conditions due to the nature of therapies prescribed and
many individuals with psoriasis experience additional challenges such as physical
and psychological comorbidities that place significant additional demands on
individuals and may undermine adherence. Viewing nonadherence to medication
as an outcome of limited personal coping resources and conflicting goals may
help to explain medication nonadherence.
Objectives To explore individuals’ perspectives of their psoriasis, medication and its
management.
Methods Twenty people with psoriasis were recruited from community samples in
England and interviewed in-depth about their perceptions of their psoriasis, med-
ication, and adherence to medication and self-management advice. Data were
analysed using Framework Analysis.
Results Participants reported that adhering to recommended treatment regimens
conflicted with the management of the physical and psychological demands of
living with psoriasis. Medication usage was viewed as a source of unresolved
emotional distress and, for some, resulted in poor self-reported adherence, which
included medication overuse, underuse and rejection of prescribed therapies. Per-
ceived lack of engagement by clinicians with participants’ self-management diffi-
culties was viewed as an additional source of stress and distress.
Conclusions Adhering to medication in psoriasis can be an additional source of
considerable emotional distress. We interpreted some episodes of nonadherence
to psoriasis medication as rational attempts by individuals to minimize distress
and to gain control over their life.
What’s already known about this topic?
• Although common, little is known about factors contributing to nonadherence to
therapies used in psoriasis.
What does this study add?
• Illness and medication beliefs and associated mood influence medication nonadher-
ence.
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• Attempts to adhere can undermine people’s ability to manage their emotional dis-
tress.
• For some patients, following prescribed medication regimens adds to rather than
relieves psoriasis-associated distress.
What are the clinical implications of this work?
• Some occurrences of nonadherence to medication in psoriasis should be recognized
as a strategic decision by the patient to reduce distress and to gain control.
• Assessing patients’ beliefs and mood, and identifying potentially conflicting health
goals may help to support medication adherence.
Psoriasis is a chronic immune-mediated inflammatory skin
condition, affecting at least 2% of the U.K. population.1 Indi-
viduals are often diagnosed before the age of 30 years2 and
therefore will use pharmacological therapies for most of adult-
hood. Medication adherence, defined as the ‘extent to which
the patients’ behaviour matches agreed recommendations from
the prescriber’, is a major barrier to optimizing the efficacy of
available therapies,3 with people typically taking only half of
their prescribed medication.4 People with psoriasis express
widespread dissatisfaction with medication,5,6 view the provi-
sion of formal support for medicines use as poor7 and experi-
ence adherence difficulties,8,9 yet few high-quality studies
have examined the influences on adherence to therapies used
in psoriasis.10
Self-regulation can be used to describe how individuals alter
their thoughts or behaviours in order to achieve a desired
goal.11 Leventhal’s Common-Sense Self-Regulatory Model (CS-
SRM)12 can offer a useful framework for exploring how indi-
viduals respond to and cope with the emotional and beha-
vioural demands involved in living with a long-term
condition (LTC).13 The framework describes the role of indi-
vidual’s illness beliefs in influencing psychological distress and
the ability to effectively manage the condition.7,14–17
An extension of the CS-SRM known as the Necessity-Con-
cerns Framework18 identifies medication-specific beliefs as also
playing a key role. Individual’s beliefs about their personal
need for medication to manage current and future health
(specific-necessity) are balanced against their concerns about
potential negative effects from medication (specific-con-
cerns).19,20 To date, no study has applied these psychological
frameworks for understanding medication adherence in psori-
asis.10
Medication adherence can be difficult, especially in situations
where an individual must focus on their long-term goals
while forgoing short-term gains and overcoming barriers,
temptations or habits.21 For example, an individual may
choose not to use their prescribed medication regularly if they
are worried about adverse effects; this behaviour may tem-
porarily improve mood, but they are no longer optimally
managing their condition. In a synthesis of qualitative research
on individuals’ perceptions of medication-taking across various
LTCs, Pound et al.22 found that appropriate medication usage
may conflict with other priorities. These included social, work
and study commitments, medication concerns and fear of
stigmatization and disclosure, with these challenges influenc-
ing medication nonadherence. One additional challenge for
those with psoriasis is the need to manage additional illnesses,
both physical and psychological,23–28 and the associated beha-
vioural risk factors for example, management of weight reduc-
tion and specific dietary demands, smoking and excessive
alcohol consumption,29–31 which can increase the risks of
exacerbating psoriasis and of developing comorbidities.32
These physical and psychological demands of managing psori-
asis place significant demands on the individual, and may
increase the likelihood of adherence difficulties. In-depth qual-
itative explorations of patient perspectives on medication use
are rare in psoriasis research.33
Nonadherence to medication may be the result of limited
personal resources, conflicting goals and priorities, and, in the
psychological literature is termed self-regulation failure.21,34
Figure 1 depicts the key processes involved in a decisional
analysis: (i) appropriate medication usage may result in the
reduction of personal resources (e.g. time and motivation) to
manage other tasks and (ii) appropriate medication usage may
result in ongoing internal conflict between a desire to adhere
and the need to address other priorities. The prevalence of
individuals with strong beliefs in the necessity of medication
and strong concerns about its usage,35 and continued psycho-
logical distress despite the successful reduction of symptoms
in inflammatory conditions36 led us to undertake an in-depth
study of patients’ experiences of psoriasis medication usage.
The aim of this qualitative study was to explore individuals’
perspectives of their psoriasis, medication and its manage-
ment.
Methods
Sampling and recruitment
Invitation e-mails were sent to potential participants with a
diagnosis of psoriasis recruited from community venues
(places of worship, libraries, community halls) and a national
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established patient support association in the U.K. A purposive
sampling strategy was used to obtain a diverse demographic
and clinical group. Of 75 invitations sent to potential partici-
pants, 36 people demonstrated interest and were sent further
details, with a final sample of 20 people recruited from the
support website (n = 14) and from the community (n = 6)
agreeing to participate in the study (Table 1).
Data collection
During October 2011 and February 2012, data were collected
via face-to-face, in-depth cognitive interviews with partici-
pants at a location convenient for them (Table S1, see Sup-
porting Information). Interview questions about medication
use were based on the self-reported adherence items from the
Medication Adherence Report Scale (MARS),19 and questions
about medication beliefs were based on items from the Beliefs
about Medicines Questionnaire (BMQ).37 Using a cognitive
interviewing approach,38,39 participants responded to items
from the MARS and the BMQ while simultaneously providing
in-depth and detailed reasons for their responses. Additional
questions were added by the interviewer to expand on indi-
vidual’s perceptions of psoriasis,12,40 emotional distress and its
management.
Individuals were recruited and interviewed sequentially
with analysis being undertaken after each three to four inter-
views, and additional questions added to the interview guide
if new relevant themes were identified. Data saturation (no
new themes emerging) was achieved after 20 interviews,
constituting the final sample for this study. Mean duration of
the interviews was 90 min. They were conducted, audiore-
corded and transcribed verbatim by R.J.T. Informed consent
was obtained from all participants prior to data collection.
Research Ethics Committee approval was obtained (reference
11059).
Data analysis
Data were analysed based on the principles of Framework
Analysis.41 Each interview was read repeatedly for the
researcher to become familiar with the content and identify
key issues and emergent themes (Stage 1). An a priori cod-
ing (thematic) framework was developed using the con-
structs of the CS-SRM and the Necessity-Concerns Framework
(Stage 2). This framework was added to by combining the
concepts, themes and relationships that emerged during the
familiarization stage. The themes identified in Stage 1 were
added as subthemes to the primary themes identified in the
a priori framework template or included as additional pri-
mary themes. At this stage, reports of limited personal
resources and goal conflict were identified as potentially rele-
vant. All primary themes and subthemes were numbered to
create a coding framework, which was then applied to all
the transcripts systematically (Stage 3). Data were then
extracted from the transcripts and sorted by primary theme
and subtheme in a standard spreadsheet (Stage 4). During
these latter stages, thematic associations and patterns were
recorded (Stage 5). Informed by the original research aims,
all themes were constantly compared within and across cases,
in order to identify similar or contrasting themes, to identify
disparities and to explore patterns and connections between
themes.
One researcher (R.J.T.) undertook the preliminary analysis
with the interpretative component undertaken using secondary
validation by a second author (L.C.). The multidisciplinary
research team comprising researchers from diverse profes-
sional backgrounds including psychology, dermatology and
pharmacy, engaged in ongoing discussion to improve the
transferability and credibility of the findings. The quality and
transparency of this research was guided by the Standards for
Reporting Qualitative Research (SRQR) recommendations.42
The ways in which an individual thinks about and responds to psoriasis and psoriasis therapies
(self-regulation)
Insufficient resources to manage multiple tasks
(self-regulation failure: under-regulation)
Choosing to use a psoriasis therapy that is time-
consuming to use may limit the personal resources 
available (time, motivation) to manage social activities 
and work commitments
Managing one task conflicts with the management of other tasks
(self-regulation failure: mis-regulation)
Choosing to use a psoriasis therapy that carries future risk to 
health, although helping to achieve the individual's short-term 
goal (managing symptoms), may conflict with the 
achievement of their long-term goal (maintaining future health)  
Fig 1. The challenges of medication adherence, in the context of self-regulation failure.
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Results
The analysis produced four overarching themes and subthemes
(Table 2).
Theme 1: depletion of personal coping resources
Adherence to psoriasis therapies depleted personal coping
resources, including time and motivation available for
other illness tasks (Table 3). Participants reported the fre-
quent collection of repeat topical prescriptions and high-
frequency applications as time-consuming and requiring
significant effort, which limited the time and motivation
available to engage in social activities. Perceived stigmatiza-
tion resulted in social avoidance, with individuals hiding
their condition from others and actively avoiding public
places or social situations. Topical therapy usage added to
the use of these avoidant coping strategies; the deleterious
effect on clothing (e.g. staining) and perceived stigmatiza-
tion resulted in participants avoiding social situations when
using topical therapies. Some believed they had to plan
their use of topical therapies in advance of any social
engagements, in order to ensure that its usage was not
visible to others. Some participants found it difficult to
participate in exercise activity due to the perceived stigma
of psoriasis, and topical therapy usage was an additional
barrier by limiting the time available to participate in
physical activity. Furthermore, adherence to therapy was
viewed as adding to employment burden; the need for
regular attendance at clinic appointments for photother-
apy/photochemotherapy was viewed as time-consuming
and participants found it extremely difficult to balance
clinic attendance with work commitments.
Table 1 Demographic and disease characteristics of participants
(N = 20)
Characteristic n
Sex
Female 9
Male 11
Ethnicity
White 18
Indian 1
Chinese 1
Employment
In paid work (full or part-time,
including self-employed)
12
In full-time education/training 3
Unemployed 1
Retired 3
Retired and voluntary work 1
Education
1 or more ‘O’ level equivalents 1
1 or more ‘A’ level equivalents 2
Trade qualifications 3
Professional qualifications 8
Degree 6
Housing
Owner-occupied/mortgaged 14
Rented from local authority/
housing association
2
Rented from a private landlord 3
Other (living with parents) 1
Psoriasis type
Chronic plaque 19
Palmoplantar psoriasis 1
Comorbid conditions
Psoriatic arthritis 3
Current treatmentsa
Topical 16
Phototherapy/photochemotherapy 1
Oral systemic 6
Biologic 1
Nonprescription (e.g. tanning
booths, Chinese medicine)
3
Past treatmentsa
Topical 18
Phototherapy/photochemotherapy 12
Traditional systemic 7
Age, mean years (range)
At study intake 472 (21–71)
When psoriasis started 234 (4–52)
aMore than one characteristic can be recorded by each
individual.
Table 2 Self-regulation failure themes and subthemes
Theme Description Subtheme
Theme 1 Depletion of personal
coping resources
1.1 Social activities
1.2 Exercise and physical
activity
1.3 Work commitments
Theme 2 Conflict with the
management of
other illness tasks
2.1 Treatment concerns
2.2 Uncertain treatment
efficacy
2.3 Stress as a causal factor of
psoriasis
2.4 Adjustment to psoriasis
Theme 3 Adherence to
medication
3.1 Use medication in
accordance with current
guidelines
3.2 Treatment holidays/
breaks
3.3 Reducing the frequency
of topical application
3.4 Increasing the duration
of topical application
3.5 Increasing topical therapy
dosage
3.6 Reject prescribed topical
therapy
Theme 4 Relationships with
healthcare
professionals as an
additional stressor
4.1 Lack of empathy with the
challenges of medication
usage
4.2 Lack of support
reinforced rejection of
psoriasis therapies
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Theme 2: conflict with the management of other illness
tasks
Adherence to psoriasis therapies conflicted with the manage-
ment of other illness tasks (Table 4). Participants expressed
ongoing internal conflict between the need to manage and
gain control over psoriasis symptoms by using prescribed
therapies, and concerns that those therapies have the potential
for adverse effects or risks of damage to future health. Partici-
pants commonly expressed major concerns about adverse
effects such as potential liver damage from methotrexate or
skin thinning from topical corticosteroids. The perception of
psoriasis as a LTC requiring life-long medication heightened
these medication concerns. Participants expressed anxiety
about prior as well as future medication use with some view-
ing their exposure to a range of different psoriasis therapies as
resulting in long-term and potentially damaging accumulation
of medication adverse effects. Some participants reported
managing the distress caused by these conflicting goals by
being vigilant to potential adverse skin damage resulting from
the use of topical corticosteroids and phototherapy/pho-
tochemotherapy. However, combined with participant uncer-
tainty in correctly identifying and detecting potential skin
changes, this served to perpetuate ongoing anxiety.
Perceived poor control of symptoms and the unpredictable
response to topical therapy was a source of internal conflict
and distress and led participants to question the necessity of
their therapy. Furthermore, some questioned whether topical
therapy usage could increase psoriasis severity and resistance to
medication, which served to perpetuate feelings of anxiety.
The inability to use alternative psoriasis therapies due to exist-
ing contraindications (e.g. comorbid conditions, adverse med-
ication effects) generated a sense of unwanted medication
dependency and lack of long-term psoriasis control that served
to increase anxiety and negative expectations of the future
course of psoriasis and its management.
Stress was viewed as a causal factor of psoriasis and exacer-
bating flares. In addition, the psychological and social conse-
quences of psoriasis were perceived as stressful and contributing
to symptom severity. Participants viewed this vicious psoria-
sis–stress cycle as particularly difficult, resulting in beliefs of
limited or no control and feelings of frustration or hopeless-
ness. Participants also expressed the belief that stress interacted
with medication response; some believed stress could interfere
with the efficacy of topical therapies, which maintained feel-
ings of limited control and distress. In addition, psoriasis ther-
apies and efforts to adhere to them were also viewed as
inherently stressful because of their impact on daily life.
The experience of relapsing and remitting flares was a key
factor in participants’ inability to adjust to their psoriasis. The
experience of unpredictable flares, despite medication usage,
perpetuated feelings of limited control and psychological dis-
tress. The unattractive effects of topical therapies were constant
reminders of the visibility of their condition and its psycho-
logical and social consequences. Furthermore, the perceived
visibility and noticeability of topical therapy usage conflicted
with the strong desire to hide the condition from others,
amplifying concerns about the negative reactions of others.
Many participants felt they had to conceal their condition
from the general public, as well as from their family, close
friends and spouse/partner. However, while recognizing the
importance of topical therapies, participants found usage of
them challenged their need to conceal their condition; partici-
pants described topical therapies as a burden to themselves
(e.g. messy to use, stains clothing), and also to their partners
or close family members.
Theme 3: adherence to medication
Adherence to psoriasis therapies depleted personal resources
and conflicted with the management of other illness tasks.
Despite these challenges and self-reported distress, some par-
ticipants reported continuing to use their psoriasis therapy as
advised to help control disease and improve quality of life
Table 3 Theme 1: depletion of personal coping resources
Subthemes Data extracts
1.1 Social activities ‘I was once sat by the pool and I heard
this woman say, “Look at that
woman’s feet,” and I felt absolutely
dreadful.’ [P1: using topical therapy]
‘So it [topical therapy] practically
destroys any chance of having a social
life or anything like that.’ [P5:
prescribed topical therapy but using
tanning beds]
‘. . . I’ll plan it [topical therapy] if I know
we will be going out or if we are
going out for a family meal or
whatever. I’ll plan to use stuff so when
we do go out, it’s not noticeable that I’ve
used anything.’ [P15: using topical
therapy and photochemotherapy]
1.2 Exercise and
physical activity
‘I feel it’s quite difficult to do activities
like swimming or anything which
exposes too much of my arms and legs
really.’ [P4: using topical therapy]
‘You’re meant to use it [topical therapy]
twice a day, which is not practical . . .
it cuts into the time that I would like
to go for a jog . . . ’ [P5: prescribed
topical therapy but using tanning beds]
1.3 Work
commitments
‘But actually, you know, if you’ve got a
job, even if it’s just a 9 to 5 job; to go
to your UVB 3 times a week for a 12-
week period, that’s quite a lot.
Let alone if you travel a lot. It then
becomes unsustainable.’ [P6: using topical
therapy, previously used phototherapy]
‘You just can’t do it [follow the topical
therapy regimen]. Especially working and
things like that, you just can’t do it.’
[P2: using topical therapy]
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(Table 5). However, in order to reduce distress, manage
uncertainty, gain control and increase the resources available
for other tasks, some participants unilaterally adjusted their
topical therapy use based on perceived symptom severity.
Managing the time-consuming nature of topical therapies
was difficult and for some, this ongoing depletion of personal
resources (including time and effort) resulted in the decision
to have ‘treatment holidays/breaks’. Some participants actively
chose to underuse their topical therapy to avoid experiencing
ongoing conflict. Thus, topical therapies were used only when
their psoriasis flares were perceived to be severe and requiring
immediate symptom management. This strategically nonadher-
ent behaviour enabled individuals to regain a manageable bal-
ance of addressing psoriasis symptoms and medication
concerns while diminishing the impact of topical therapies on
daily life, feelings of uncertainty and distress. Some partici-
pants had sporadic topical therapy overuse (increasing the du-
ration of topical application), interspersed with topical therapy
underuse, which appeared to be intentionally compensatory
for lack of regular therapy use. For those who were using
their topical therapies regularly, topical therapy overuse (in-
creasing topical dosage) was done in order to address
Table 4 Theme 2: conflict with the management of other illness tasks
Subthemes Data extracts
2.1 Treatment concerns ‘ . . . I worry about the damage to my liver with methotrexate and also for my skin with the creams as well,
because I know the steroids can damage your skin long term.’ [P13: using topical and oral therapy]
‘I don’t like the injections, it’s kind of really painful and I get really nervous about it.’ [P3: using a biologic]
‘ . . . It worries me the fact that I’ve been treating psoriasis for over 40 years now and so I’m worried about
the effect of those treatments I have had over those years.’ [P16: using topical therapy]
‘I do kind of look at my skin but I can’t tell [if it’s thinning or not]. How would you tell? Nobody ever notices,
when I go to give blood, no one ever comments on it or anything like that.’ [P2: using topical therapy]
‘Sometimes I worry because I don’t want to become too dependent on medication, because this medication
could be taken away from me at any time. It really depends on the way the NHS funding goes.’ [P3: using a
biologic]
2.2 Uncertain treatment
efficacy
‘ . . . Sometimes I feel that the treatments aren’t stopping the psoriasis from increasing and sometimes I feel that
the psoriasis is quite resistant and will increase, despite using the treatment . . . I’m not sure overall, whether they
are stopping it from getting worse.’ [P4: using topical therapy]
‘ . . . If this treatment that I am having now stops working . . . I don’t even want to think about it really . . . because I
know that at my age and given the other health problems that I have got . . . it’s eliminated other tablet forms
of treatments that um . . . I’ve had to stop because of the side-effects.’ [P1: using topical therapy]
‘What makes me feel uncertain about it is, you know, what other side-effects it could pose . . . could it make
my psoriasis worse if I ever stop taking it . . . I do worry whether if I ever stopped the medication, could
something trigger it off to come back much, much worse than it was before. So that’s a worry.’ [P3: using a
biologic]
‘I find it somewhat distressing and I have to make the decision, not knowing really what the outcome is. Not
knowing if I stop using a particular cream whether I’m going to get more symptoms or if I get less.’ [P4:
using topical therapy]
2.3 Stress as a casual
factor of psoriasis
‘I was under a lot of stress so I did get lots of flare-ups.’ [P10: using oral therapy]
‘ . . . Being fairly active, not being able to do want I want to do, is very, very annoying and it’s highly stressful
and it’s a vicious circle. So that brings on psoriasis even worse.’ [P5: prescribed topical therapy but using
tanning beds]
‘ . . . It depends on how stressed I get at work . . . I can be using my creams and doing my daily routine and it will
still manage to creep back up to a level where I don’t find acceptable.’ [P15: using topical therapy and
photochemotherapy]
‘ . . . I can either miss my UVB, and I know it’s not great and I know I’m prescribed a course of it, or I can
tell the people who I work for that I can’t do this trip because I’ve got my psoriasis treatment . . . the latter
would cause me so much more stress than the former and make my psoriasis worse, so you have to make decisions about
things.’ [P6: using topical therapy, previously used phototherapy]
I’ve only been on it 5 months, and I haven’t really noticed a major difference but then I have had quite a lot
of stress . . . I think the stress has counteracted the effectiveness of the drug.’ [P3: using a biologic]
2.4 Adjustment to
psoriasis
‘ . . . It’s more upsetting when it comes back. Because you think, this is it, I’ve found a cure but there isn’t a cure.’
[P14: using oral therapy]
‘I feel really self-conscious because I’ve got this sort of gunk all over my head . . . if I put it on in the morning, I
can’t go out until the evening . . . ’ [P11: using topical therapy]
‘ . . . It’s the most awful thing in the world; it smells like you are creosoting a fence. So I don’t want to put my
partner through that.’ [P11: using topical therapy]
‘I used to put greasy stuff in and you would be all sticky and then you would have to wash it all out and that
took ages to wash out. I’m almost having nightmares just thinking about it.’ [P7: using topical and oral
therapy]
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uncertainty about topical therapy efficacy and gain control
over troubling symptoms.
For some participants, heightened medication concerns,
feelings of low controllability and dissatisfaction with the
management of symptoms resulted in the decision to priori-
tize mood management and other illness tasks and use alterna-
tive therapies, which included the use of indoor ultraviolet
radiation exposure in the form of tanning beds.
Theme 4: relationships with healthcare professionals as
an additional stressor
Participants experienced medication use to be challenging and
distressing, but participants believed this was rarely acknowl-
edged in clinic (Table 6). Participants reported that clinicians
appeared to lack empathy with the effects of psoriasis thera-
pies and that neither their medication concerns nor inability
to control symptoms were acknowledged. This added to the
internal conflict between medication usage and medication
concerns and uncertainty, maintaining psychological distress.
Perceived unacknowledged goal conflict and severe distress
seemed to exacerbate self-management difficulties, limiting
opportunities for shared treatment decision making and isolat-
ing participants. Most of those interviewed indicated that they
made medication decisions alone and this led to deviations
from recommended regimens in terms of both medication
underuse and overuse. Some participants withdrew from con-
ventional healthcare support and sought alternative therapies.
Discussion
We undertook an in-depth study of patient perspectives in
treatment decision making and adherence to therapy in psoria-
sis. We found that individuals’ reported beliefs about their
psoriasis and medication and associated mood played a crucial
role in medication adherence. One notable finding is that
medication underuse and overuse were influenced by distinct
beliefs about psoriasis and psoriasis medication. Medication
underuse seemed to be driven by concerns about the potential
for adverse effects, perceived poor control of symptoms and
feelings of anxiety. Medication overuse was influenced by
experiences of unpredictable flares during medication usage,
perceptions of uncertain treatment effectiveness and frustration.
These results suggest nonadherence to psoriasis medication
may be a function of depleted personal resources and of con-
flicting demands or priorities, differing aspects of what is
known as self-regulation failure.21,34 Topical therapy was
viewed as time-consuming and messy, and its use was viewed
as increasing the likelihood of socially avoidant behaviours,
creating additional employment/financial burdens and
Table 5 Theme 3: adherence to medication
Subtheme Data extracts
3.1 Use medication in
accordance with current
guidelines
‘I think you would be so withdrawn if you didn’t have any of those treatments . . . I would find it
extremely difficult to cope.’ [P15: using topical therapy and photochemotherapy]
‘I’ve only ever stopped taking it once and that was on the instructions of the doctor because they
suspected a possible adverse reaction.’ [P3: using a biologic]
‘I use it regularly every day because that’s how it has been prescribed.’ [P1: using topical therapy]
3.2 Treatment holidays/breaks ‘Every now and again I have a day when I say sod it, that’s it, I can’t do this 7 days a week, I’m only
going to do this 6 days a week.’ [P16: using topical therapy]
‘If I’m working from home for a week, then I might miss my scalp stuff for a couple of days, purely
because I think no one is going to see it.’ [P11: using topical therapy]
3.3 Reducing the frequency of
topical application
‘ . . . I have been concerned in the past about skin thinning . . . I just basically respond to what I need.’
[P2: using topical therapy]
‘I sometimes go 10 months without using any . . . sometimes I don’t feel that it is bad enough. And
that can sometimes be because it is not bad enough, or that it’s not affecting my lifestyle so I just
choose that I don’t want to put on my creams.’ [P6: using topical therapy, previously used
phototherapy]
3.4 Increasing the duration of
topical application
‘Often I alter the dose if I’m feeling that my psoriasis is particularly bad at the time or if I need to get
my psoriasis to a manageable level . . . Leave it on for longer, that kind of thing.’ [P11: using topical
therapy]
3.5 Increasing topical therapy
dosage
‘ . . . I haven’t discovered over these years whether there is any way of telling whether putting more and
more on will work, it just seems to be how my body reacts after a certain period of time.’ [P4: using
topical therapy]
‘If I’m honest, using certain creams, there is probably the odd tendency to use too much, rather than too
little.’ [P16: using topical therapy]
3.6 Reject prescribed topical
therapy
‘There is no point me taking the strongest medication now, because the moment you stop taking it, it
comes back worse within a week. So you go through a lot of effort, discomfort and inconvenience for 1 week’s
benefit? That’s just plain rubbish . . . ’ [P5: prescribed topical therapy but using tanning beds]
‘I just gave up because it wasn’t getting any better and it wasn’t working so I wasn’t prepared to keep
paying for the treatments which were doing nothing for me.’ [P9: prescribed topical therapy but
using herbal therapies]
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reducing or ending participation in physical activities. These
factors are recognized problems in this population43–45 and all
were perceived as contributing to ongoing psychological dis-
tress.
The need to manage psoriasis symptoms with prescribed
medication conflicted with the need to manage concerns about
adverse effects. Perceived uncertainty about treatment effec-
tiveness and views that they had little control over symptoms
added to internal conflict. Participants reported stress as a
cause and trigger of psoriasis, and described ongoing struggles
between their need to limit exposure to stressors and their
desire to use psoriasis therapies perceived as stressful. Further-
more, the use of visible topical therapies undermined their
desire to hide their condition from others. These challenges
resulted in unresolved emotional distress, little perceived con-
trol and high levels of uncertainty. Findings reflected other
evidence that highlighted perceived lack of support from
healthcare providers, especially within general practice man-
agement,7,33,46 and in the current study this further under-
mined optimal medication usage.
Despite these challenges, some people reported continuing
to use their psoriasis therapy as prescribed, although this led
to continued high levels of unresolved distress. Others man-
aged this distress by adjusting their medication usage based
on perceived symptom severity, resulting in medication non-
adherence, both medication underuse and overuse. A further
group chose to reject their prescribed medication altogether
and seek support from alternative sources.
Factors influencing medication adherence in psoriasis are
largely unknown, with few studies exploring the role of
patient perspectives in treatment decision making.10 Demo-
graphic and disease factors have inconsistent relationships with
adherence, both in psoriasis10 and in other LTCs.47
Understanding the modifiable factors (patient perceptions) for
nonadherence can help to develop effective adherence inter-
ventions. Increased distress and low patient satisfaction with
care and therapy are associated with nonadherence in psoria-
sis10 and we found that individual’s beliefs about psoriasis
and its medication also play an important role in medication
adherence. Complex adherence challenges and strategic modi-
fication of treatment regimens have been reported in other
LTCs22 and this study demonstrates that similar challenges are
also present in psoriasis. Nonadherence to medication may be
viewed as an outcome of limited personal resources and con-
flicting goals, and therefore seen as a strategic and rational
attempt to actively manage and limit the impact of ongoing
emotional distress that results from conflicting demands and
priorities.
The majority of participants recruited were using topical
therapies and thus the findings may not be transferable to
individuals whose treatment included more complex regimens.
We acknowledge the potential for sampling bias; self-reported
distress and illness and medication burden in this study could
be due to participants primarily being recruited through sup-
port groups. Additionally, levels of adherence disclosed by the
participants were self-reported rather than assessed by an
objective measure. Despite these limitations, our qualitative
methods have provided new insights and a richer understand-
ing of factors that influence adherence in psoriasis and indi-
viduals’ perceptions of the challenges of treatment decision
making, which have not been captured in previous survey
studies. The SRQR guidelines42 informed the design, conduct
and analysis of this qualitative research, resulting in high-qual-
ity data and contributed to the credibility of the findings.
We suggest using a nonjudgmental approach that recognizes
barriers to adherence48 and encouraging patients to discuss
Table 6 Theme 4: relationships with healthcare professionals as an additional stressor
Subthemes Data extracts
4.1 Lack of empathy with the
challenges of medication usage
‘ . . . They don’t understand that you are wearing stuff on your head that makes you smell like you’re
painting fences . . . it’s really frustrating, they [clinicians] need to look at the impact of these
treatments, maybe then they could understand why people aren’t sticking to them.’ [P11: using
topical therapy]
‘My [GP] said, “Well use the coal tar during the day,” and I said, “Well I can’t because it’s too
messy . . . ,” and all she said was “Oh, well just wear gloves.” But it’s impossible as I’m working
with papers all the time.’ [P9: prescribed topical therapy but using herbal therapies]
‘It did kind of put me under a bit of stress, it affected my condition hugely. I really don’t
understand why [I was unable to be prescribed my preferred biologic], I mean, I try not to think
about it too much but at the time it did cause me a lot of worry and upset . . . there might have been
a very good reason behind it but they didn’t want to share it with me.’ [P3: prescribed a biologic]
‘I had to really look [possible side-effects] up myself on the Internet. She [clinician] was quite blase
about it . . . and I was reading all these blogs about side-effects which worried me, so I wasn’t happy
that I wasn’t getting all the information.’ [P13: using topical and oral therapy]
‘Nobody has ever really asked me how I feel about my psoriasis or how I deal with my psoriasis.
Or what my feelings are. Nobody has ever asked me that.’ [P15: using topical therapy and
photochemotherapy]
4.2 Lack of support reinforced
rejection of psoriasis therapies
‘I stopped going [to the GP] because they weren’t helping . . . because nothing [treatment] had
worked there wasn’t really much point in trying another one.’ [P9: prescribed topical therapy but
using herbal therapies]
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key factors that may influence nonadherence: their beliefs
about psoriasis; medication and its management; how medica-
tion fits into their lives and any barriers they face. This
approach may help patients identify potential solutions, help
support psychological well-being and enhance medication
adherence. The identification and explicit recognition of
potentially conflicting goals may itself be therapeutic and
reduce distress.49 It is important to recognize that patients can
still be experiencing considerable distress and illness and treat-
ment uncertainty, even if they are adhering to their medica-
tion. Future research should use these findings to inform the
development and evaluation of an adherence intervention and
utilize a longitudinal study design to examine the prospective
relationships between illness and medication beliefs and psy-
chological distress with adherence to psoriasis medication.
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